印度女性乳腺癌的 HER-2/neu 肿瘤标志物。
Cancer biomarker HER-2/neu in breast cancer in Indian women.
机构信息
Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India.
Department of General Surgery, Government Medical College, Miraj, Maharashtra, India.
出版信息
Breast Cancer (Dove Med Press). 2011 Mar 29;3:21-6. doi: 10.2147/BCTT.S17108. eCollection 2011.
AIM AND OBJECTIVES
In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.
MATERIALS AND METHODS
Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.
RESULTS
Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.
CONCLUSION
HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.
目的和目标
在印度乳腺癌女性中，HER-2/neu 基因在 30%的病例中扩增。血清 HER-2/neu 水平升高与早期乳腺癌患者的不良临床预后和生存率降低相关，检测该指标可能有助于疾病的管理。因此，本研究旨在评估乳腺癌患者的血清 HER-2/neu 水平，并将其与其他预后因素相关联。
材料和方法
研究了 207 例乳腺癌患者、15 例良性乳腺疾病（BBD）患者和 175 名年龄匹配的健康对照者的血清 HER-2/neu 水平。比较了患者的年龄、绝经状态、淋巴结状况以及雌激素受体（ER）和孕激素受体（PgR）状态与血清 HER-2/neu 水平的关系。
结果
血清 HER-2/neu 过表达与年龄、疾病分期和阳性淋巴结状态相关，但与绝经状态无关。血清 HER-2/neu 水平与激素受体阳性呈负相关。
结论
在印度乳腺癌女性中，无论其 ER 和 PgR 激素受体状态如何，都应更频繁地进行 HER-2/neu 血清检测。当无法获得乳腺组织样本时，ELISA 是一种可靠且经济的评估肿瘤 HER-2/neu 状态的工具。
Zotero 插件